Recent preclinical data extend this mechanism across disease settings: in an abdominal aortic aneurysm model, montelukast curtailed aneurysm growth while downregulating MMP-9 (and MMP-2) in the aortic wall via AMPK-mTOR pathway effects, aligning MMP-9 suppression with structural protection of the vessel [111,112]. This evidence concerns the gene MMP9 and abdominal aortic aneurysm.